ERBB2 and breast carcinoma: In the same phase 1 trial, T-DXd demonstrated antitumor activity also in the cohort of patients with HER2-low–expressing breast cancer refractory to standard therapies (n = 54) [26]: confirmed ORR was 37.0%, with median duration of response (DOR) of 10.4 months.